Science
What five randomized controlled trials tell us about CoQ10 and fertility outcomes
Coenzyme Q10 is arguably the most studied fertility-specific supplement after folate. The rationale is mechanistically compelling: mature oocytes require extraordinary mitochondrial energy to complete meiosis correctly. When mitochondrial function is impaired — as it naturally becomes with age — chromosomal segregation errors increase, leading to aneuploid embryos that fail to implant or miscarry.
Meta-analysis spotlight |
A 2020 systematic review and meta-analysis (PMC7550497) analyzed 5 randomized controlled trials in 449 infertile women undergoing ART. Women receiving CoQ10 had a clinical pregnancy rate of 28.8%, compared to 14.1% in the placebo group — a statistically significant difference (OR 2.44, p=0.006). The benefit held when women with PCOS and poor ovarian response were analyzed separately. |
A separate randomized controlled trial in young women with diminished ovarian reserve found that 600 mg of CoQ10 daily for 60 days significantly improved ovarian response and embryo quality markers. Animal studies have shown even more dramatic effects, with aged mice on CoQ10 recovering egg quality metrics comparable to young animals.
While more large-scale human trials are needed, the mechanistic rationale and existing RCT data make CoQ10 one of the few fertility supplements with genuine evidence-based support — particularly for women over 35, those with diminished ovarian reserve, or PCOS.
Read the full meta-analysis: pmc.ncbi.nlm.nih.gov/articles/PMC7550497/
